Radioactive 'Smart Bomb' tested for tough prostate cancer
NCT ID NCT07259213
Summary
This study is testing a new radioactive drug called 161Tb-RAD402 for men with advanced prostate cancer that has stopped responding to standard hormone treatments. The drug is designed to seek out and deliver radiation directly to prostate cancer cells. The study will first find the safest dose and then see if the treatment can reduce cancer activity in about 73 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wollongong Hospital
RECRUITINGWollongong, New South Wales, 2500, Australia
Conditions
Explore the condition pages connected to this study.